NR1H4 and type 2 diabetes mellitus: Oral synthetic FXR antagonists may be of potential translational value in the clinical treatment of T2D (72) Moreover, both BA sequestrants and apical sodium-dependent BA transporter inhibitors can reduce BA absorption and have a therapeutic effect on T2D by activating FXR (73).